Sarah Zohar – HeKA team

Sarah Zohar
DR Inserm

email: first name dot last name at inria dot fr

email: first name dot last name at inserm dot fr
postal address: Paris SantéCampus, 10 rue d’Oradour sur Glane, 75015 Paris
web page: Orcid
bio :

Head of HeKA, Sarah Zohar is an expert in innovative methods for interventional and observational health data modeling including drug and Digital Medical Devices evaluation. She has made many methodological contributions for exploratory clinical trials and real-life health data analysis proposing novel methods and approaches that have been applied in cancer, rare diseases, resistance to antibiotics and pediatric clinical trials among other fields. She has collaborated with physicians in the designing, planning, conducting and analyzing clinical trials and she has developed new approaches in collaboration with international methodological experts from USA, Japan and Europe. She is a member at the French HTA for Medical Device reimbursement commission, that is, CNEDIMTS at HAS (“Haute Autorité de Santé”). She is currently participating at the French HTA, HAS, working group on “Digital medical devices for professional use”. She has participated to a workgroup for the access to innovative drugs at French HTA, this workgroup work was published in BMJ Evidence Based Medicine 2023. (http://dx.doi.org/10.1136/bmjebm-2022-112091). She is part of the European taskforce of EIT Health and the French Ministry of Solidarity and Health for “harmonization of clinical studies criteria & methodologies in Europe for the evaluation of digital medical devices. She has been invited to speak as Key note speaker or contributor at a number of international scientific meetings.

Selected Research Projects

European project “FAIR” EU H2020-SC1-2019-847786-2, “Flagellin aerosol therapy as an immunomodulatory adjunt to the antibiotic treatment of drug resistant bacterial pneumonia”, Workpackage co-leader “Development of a translational modelling and simulation platform and Bayesian adaptive design for flagellin PK/PD”.

ANR PEPR Digital Health (National French) – SMATCH -“Statistical and AI based Methods for Advanced Clinical Trials CHallenges in Digital Health”, co-PI.

European ITN MARIE SKŁODOWSKA-CURIE ACTIONS “ORGESTRA” HORIZON-MSCA-2022-DN-01-01, “Organoid technologies for disease modeling, drug discovery and development for rare diseases”, Workpackage leader “Pathway to clinic”.

ORCID: 0000-0002-8429-2340

Publications
Publications HAL de sarah, zohar

2024

Journal articles

ref_biblio: Antoine Vanier, Judith Fernandez, Sophie Kelley, Lise Alter, Patrick Semenzato, et al.. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. BMJ Evidence-Based Medicine, 2024, 29 (1), pp.1-5. ⟨10.1136/bmjebm-2022-112091⟩. ⟨hal-04056273⟩
Accès au texte intégral et bibtex

ref_biblio: Sandrine Boulet, Moreno Ursino, Robin Michelet, Linda Bs Aulin, Charlotte Kloft, et al.. Bayesian framework for multi-source data integration-Application to human extrapolation from preclinical studies. Statistical Methods in Medical Research, 2024, Statistical Methods in Medical Research, ⟨10.1177/09622802241231493⟩. ⟨hal-04513000⟩
Accès au bibtex

2023

Journal articles

ref_biblio: Silvia Calderazzo, Sergey Tarima, Carissa Reid, Nancy Flournoy, Tim Friede, et al.. Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. Statistics in Biopharmaceutical Research, 2023, pp.1-17. ⟨10.1080/19466315.2023.2211023⟩. ⟨hal-04336804⟩
Accès au bibtex

ref_biblio: Benjamin Duputel, Nigel Stallard, François Montestruc, Sarah Zohar, Moreno Ursino. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial. Statistical Methods in Medical Research, 2023, 32 (5), pp.963-977. ⟨10.1177/09622802231160554⟩. ⟨hal-04126394⟩
Accès au bibtex

2022

Journal articles

ref_biblio: Christian Röver, Moreno Ursino, Tim Friede, Sarah Zohar. A straightforward meta‐analysis approach for oncology phase I dose‐finding studies. Statistics in Medicine, 2022, 41 (20), pp.3915-3940. ⟨10.1002/sim.9484⟩. ⟨hal-03864767⟩
Accès au texte intégral et bibtex

ref_biblio: William Hua, Hongyuan Mei, Sarah Zohar, Magali Giral, Yanxun Xu. Personalized Dynamic Treatment Regimes in Continuous Time: A Bayesian Approach for Optimizing Clinical Decisions with Timing. Bayesian Analysis, 2022, 17 (3), ⟨10.1214/21-BA1276⟩. ⟨hal-03863019⟩
Accès au bibtex

ref_biblio: Emma Gerard, Sarah Zohar, Hoai‐thu Thai, Christelle Lorenzato, Marie‐karelle Riviere, et al.. Bayesian dose‐regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. Biometrics, 2022, ⟨10.1111/biom.13433⟩. ⟨hal-03141298⟩
Accès au texte intégral et bibtex

ref_biblio: Jérôme Lambert, Etienne Lengliné, Raphaël Porcher, Rodolphe Thiébaut, Sarah Zohar, et al.. Enriching single-arm clinical trials with external controls: possibilities and pitfalls. Blood Advances, In press, ⟨10.1182/bloodadvances.2022009167⟩. ⟨hal-03914596⟩
Accès au bibtex

2021

Journal articles

ref_biblio: Emma Gerard, Sarah Zohar, Christelle Lorenzato, Moreno Ursino, Marie‐karelle Riviere. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. Statistics in Medicine, 2021, ⟨10.1002/sim.9113⟩. ⟨hal-03335297⟩
Accès au bibtex

ref_biblio: Thomas Murray, Peter Thall, Frederique Schortgen, Pierre Asfar, Sarah Zohar, et al.. Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock. Bayesian Analysis, 2021, 16 (3), ⟨10.1214/20-BA1229⟩. ⟨hal-03864768⟩
Accès au texte intégral et bibtex

ref_biblio: Emma Gerard, Sarah Zohar, Christelle Lorenzato, Moreno Ursino, Marie‐karelle Riviere. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. Statistics in Medicine, 2021, ⟨10.1002/sim.9113⟩. ⟨hal-03288022⟩
Accès au texte intégral et bibtex

ref_biblio: Robin Michelet, Moreno Ursino, Sandrine Boulet, Sebastian Franck, Fiordiligie Casilag, et al.. The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. Pharmaceutics, 2021, 13 (5), pp.601. ⟨10.3390/pharmaceutics13050601⟩. ⟨hal-03215662⟩
Accès au texte intégral et bibtex

ref_biblio: Adrien Coulet, Stéphanie Allassonniere, François Angoulvant, Anita Burgun, Xiaoyi Chen, et al.. L’équipe-projet HeKA. Bulletin de l’Association Française pour l’Intelligence Artificielle, 2021, 112, pp.29-32. ⟨hal-03485904⟩
Accès au texte intégral et bibtex

ref_biblio: Guoqing Diao, Anand Vidyashankar, Sarah Zohar, Sandrine Katsahian. Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies. Statistics in Biosciences, 2021, 13 (1), pp.142-159. ⟨10.1007/s12561-020-09288-x⟩. ⟨hal-03863045⟩
Accès au bibtex

ref_biblio: Moreno Ursino, Christian Röver, Sarah Zohar, Tim Friede. Random-effects meta-analysis of Phase I dose-finding studies using stochastic process priors. Annals of Applied Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩. ⟨hal-03206436⟩
Accès au texte intégral et bibtex

ref_biblio: Adrien Ollier, Sarah Zohar, Satoshi Morita, Moreno Ursino. Estimating Similarity of Dose–Response Relationships in Phase I Clinical Trials—Case Study in Bridging Data Package. International Journal of Environmental Research and Public Health, 2021, 18 (4), pp.1639. ⟨10.3390/ijerph18041639⟩. ⟨hal-03878713⟩
Accès au texte intégral et bibtex

2020

Journal articles

ref_biblio: Pierre-François Dequin, Nicholas Heming, Ferhat Meziani, Gaëtan Plantefève, Guillaume Voiriot, et al.. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19. JAMA Cardiology, 2020, 324 (13), pp.1298. ⟨10.1001/jama.2020.16761⟩. ⟨hal-03863060⟩
Accès au bibtex

ref_biblio: Nigel Stallard, Lisa Hampson, Norbert Benda, Werner Brannath, Thomas Burnett, et al.. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.483-497. ⟨10.1080/19466315.2020.1790415⟩. ⟨hal-03122983⟩
Accès au bibtex

ref_biblio: Cornelia Ursula Kunz, Silke Jörgens, Frank Bretz, Nigel Stallard, Kelly van Lancker, et al.. Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.461-477. ⟨10.1080/19466315.2020.1799857⟩. ⟨hal-03122985⟩
Accès au bibtex

ref_biblio: Pierre-François Dequin, Amélie Le Gouge, Elsa Tavernier, Bruno Giraudeau, Sarah Zohar. Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.478-482. ⟨10.1080/19466315.2020.1800509⟩. ⟨hal-03122980⟩
Accès au bibtex

ref_biblio: Adrien Ollier, Satoshi Morita, Moreno Ursino, Sarah Zohar. An adaptive power prior for sequential clinical trials – Application to bridging studies. Statistical Methods in Medical Research, 2020, 29 (8), pp.2282-2294. ⟨10.1177/0962280219886609⟩. ⟨hal-03863036⟩
Accès au bibtex

ref_biblio: Adrien Ollier, Satoshi Morita, Moreno Ursino, Sarah Zohar. An adaptive power prior for sequential clinical trials – Application to bridging studies. Statistical Methods in Medical Research, 2020, 29 (8), pp.2282-2294. ⟨10.1177/0962280219886609⟩. ⟨hal-03878712⟩
Accès au texte intégral et bibtex

ref_biblio: Sandrine Boulet, Moreno Ursino, Peter F Thall, Bruno Landi, Céline Lepere, et al.. Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. Statistical Methods in Medical Research, 2020, 38 (12), Ahead of print. ⟨10.1177/0962280219841082⟩. ⟨inserm-02456624⟩
Accès au texte intégral et bibtex

2019

Journal articles

ref_biblio: Camille Aupiais, Corinne Alberti, Thomas Schmitz, Olivier Baud, Moreno Ursino, et al.. A Bayesian non-inferiority approach using experts’ margin elicitation – application to the monitoring of safety events. BMC Medical Research Methodology, 2019, 19 (1), pp.187. ⟨10.1186/s12874-019-0826-5⟩. ⟨inserm-02456619⟩
Accès au texte intégral et bibtex

ref_biblio: Adrien Ollier, Satoshi Morita, Moreno Ursino, Sarah Zohar. An adaptive power prior for sequential clinical trials – Application to bridging studies. Statistical Methods in Medical Research, 2019, pp.096228021988660. ⟨10.1177/0962280219886609⟩. ⟨inserm-02456616⟩
Accès au bibtex

ref_biblio: Janet S Soul, Ronit Pressler, Marilee Allen, Geraldine Boylan, Heike Rabe, et al.. Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric Research, 2019, 85 (7), pp.943-954. ⟨10.1038/s41390-018-0242-2⟩. ⟨hal-02149297⟩
Accès au texte intégral et bibtex

ref_biblio: Moreno Ursino, Ying Yuan, Corinne Alberti, Emmanuelle Comets, Geraldine Favrais, et al.. A dose finding design for seizure reduction in neonates. Journal of the Royal Statistical Society: Series C Applied Statistics, 2019, 68 (2), pp.427-444. ⟨10.1111/rssc.12289⟩. ⟨hal-03862983⟩
Accès au texte intégral et bibtex

ref_biblio: Peter Thall, Moreno Ursino, Véronique Baudouin, Corinne Alberti, Sarah Zohar. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Statistical Methods in Medical Research, 2019, 28 (2), pp.404-418. ⟨10.1177/0962280217726803⟩. ⟨hal-03862933⟩
Accès au bibtex

ref_biblio: Shing Lee, Moreno Ursino, Ying Kuen Cheung, Sarah Zohar. Dose-finding designs for cumulative toxicities using multiple constraints. Biostatistics, 2019, 20 (1), pp.17-29. ⟨10.1093/biostatistics/kxx059⟩. ⟨inserm-02456629⟩
Accès au texte intégral et bibtex

ref_biblio: Géraldine Favrais, Moreno Ursino, Catherine Mouchel, Estelle Boivin, Vincent Jullien, et al.. Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1) study protocol of a phase II trial. BMJ Open, 2019, 9 (1), pp.e022739. ⟨10.1136/bmjopen-2018-022739⟩. ⟨hal-02049819⟩
Accès au texte intégral et bibtex

ref_biblio: Sandrine Boulet, Moreno Ursino, Peter F Thall, Anne-Sophie Jannot, Sarah Zohar. Bayesian variable selection based on clinical relevance weights in small sample studies—Application to colon cancer. Statistics in Medicine, 2019, 38 (12), pp.2228-2247. ⟨10.1002/sim.8107⟩. ⟨hal-02120840⟩
Accès au texte intégral et bibtex

2018

Journal articles

ref_biblio: Tim Friede, Martin Posch, Sarah Zohar, Corinne Alberti, Norbert Benda, et al.. Recent advances in methodology for clinical trials in small populations the InSPiRe project. Orphanet Journal of Rare Diseases, 2018, 13 (1), pp.186. ⟨10.1186/s13023-018-0919-y⟩. ⟨hal-01935072⟩
Accès au texte intégral et bibtex

ref_biblio: Paola Berchialla, Sarah Zohar, Ileana Baldi. Bayesian sample size determination for phase IIA clinical trials using historical data and semi‐parametric prior’s elicitation. Pharmaceutical Statistics, 2018, 18 (2), pp.198-211. ⟨10.1002/pst.1914⟩. ⟨inserm-02456626⟩
Accès au bibtex

ref_biblio: Paola Berchialla, Sarah Zohar, Ileana Baldi. Bayesian sample size determination for phase IIA clinical trials using historical data and semi‐parametric prior’s elicitation. Pharmaceutical Statistics, 2018, 18 (2), pp.198-211. ⟨10.1002/pst.1914⟩. ⟨hal-03862856⟩
Accès au bibtex

ref_biblio: Camille Aupiais, Sarah Zohar, Garry Taverny, Enora Le Roux, Rym Boulkedid, et al.. Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. Archives of Disease in Childhood, 2018, pp.archdischild-2018-314874. ⟨10.1136/archdischild-2018-314874⟩. ⟨hal-03864775⟩
Accès au bibtex

ref_biblio: Camille Aupiais, Sarah Zohar, Garry Taverny, Enora Le Roux, Rym Boulkedid, et al.. Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. Archives of Disease in Childhood, 2018, pp.archdischild-2018-314874. ⟨10.1136/archdischild-2018-314874⟩. ⟨inserm-02456631⟩
Accès au bibtex

ref_biblio: Caroline Petit, Adeline Samson, Satoshi Morita, Moreno Ursino, Vincent Jullien, et al.. Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. Statistical Methods in Medical Research, 2018, 27 (6), pp.1860-1877. ⟨10.1177/0962280216671348⟩. ⟨hal-01623760⟩
Accès au texte intégral et bibtex

ref_biblio: Frank Miller, Sarah Zohar, Nigel Stallard, Jason Madan, Martin Posch, et al.. Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17 (3), pp.214-230. ⟨10.1002/pst.1848⟩. ⟨hal-03864774⟩
Accès au bibtex

ref_biblio: Tim Friede, Corinne Alberti, Norbert Benda, Emmanuelle Comets, Alex Dmitrienko, et al.. Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17 (3), pp.214-230. ⟨10.1002/pst.1848⟩. ⟨inserm-02456642⟩
Accès au bibtex

ref_biblio: A. Toumazi, E. Comets, C. Alberti, T. Friede, F. Lentz, et al.. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine, 2018, 157, pp.163-177. ⟨10.1016/j.cmpb.2018.01.023⟩. ⟨hal-03864772⟩
Accès au bibtex

ref_biblio: Michael Pearce, Siew Wan Hee, Jason Madan, Martin Posch, Simon Day, et al.. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. BMC Medical Research Methodology, 2018, 18 (1), pp.20. ⟨10.1186/s12874-018-0475-0⟩. ⟨inserm-01706249⟩
Accès au texte intégral et bibtex

ref_biblio: Marie-Karelle Riviere, Ying Yuan, Jacques-Henri Jourdan, Frédéric Dubois, Sarah Zohar. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research, 2018, 27 (2), pp.466-479. ⟨10.1177/0962280216631763⟩. ⟨hal-03864773⟩
Accès au bibtex

2017

Journal articles

ref_biblio: Nigel Stallard, Frank Miller, Simon Day, Siew Wan Hee, Jason Madan, et al.. Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical Journal, 2017, 59 (4), pp.609-625. ⟨10.1002/bimj.201500228⟩. ⟨inserm-02456649⟩
Accès au texte intégral et bibtex

ref_biblio: Moreno Ursino, Sarah Zohar, Frederike Lentz, Corinne Alberti, Tim Friede, et al.. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal, 2017, 59 (4), pp.804-825. ⟨10.1002/bimj.201600084⟩. ⟨hal-01560222⟩
Accès au texte intégral et bibtex

ref_biblio: Roman Rouzier, Sébastien Gouy, Frédéric Selle, Eric Lambaudie, Anne Floquet, et al.. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer, 2017, 70, pp.133 – 142. ⟨10.1016/j.ejca.2016.09.036⟩. ⟨hal-01658616⟩
Accès au bibtex

ref_biblio: Peter F Thall, Moreno Ursino, Véronique Baudouin, Corinne Alberti, Sarah Zohar. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Statistical Methods in Medical Research, 2017, 28 (2), pp.404-418. ⟨10.1177/0962280217726803⟩. ⟨hal-02016667⟩
Accès au texte intégral et bibtex

2016

Journal articles

ref_biblio: Florentia Kaguelidou, Corinne Alberti, Valerie Biran, Olivier Bourdon, Caroline Farnoux, et al.. Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. PLoS ONE, 2016, 11 (12), pp.e0166207. ⟨10.1371/journal.pone.0166207⟩. ⟨hal-01477416⟩
Accès au texte intégral et bibtex

ref_biblio: Siew Wan Hee, Adrian Willis, Catrin Tudur Smith, Simon Day, Frank Miller, et al.. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases, 2016, 12 (1), pp.44. ⟨10.1186/s13023-017-0597-1⟩. ⟨inserm-01481651⟩
Accès au texte intégral et bibtex

ref_biblio: Elisabeth Chéreau, Catherine Uzan, Emmanuelle Boutmy-Deslandes, Sarah Zohar, Corinne Bézu, et al.. Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. PLoS ONE, 2016, 11 (6), pp.e0156096. ⟨10.1371/journal.pone.0156096⟩. ⟨hal-01344161⟩
Accès au texte intégral et bibtex

ref_biblio: Siew Wan Hee, Thomas Hamborg, Simon Day, Jason Madan, Frank Miller, et al.. Decision-theoretic designs for small trials and pilot studies: A review. Statistical Methods in Medical Research, 2016, 25 (3), pp.1022-1038. ⟨10.1177/0962280215588245⟩. ⟨inserm-02456662⟩
Accès au texte intégral et bibtex

ref_biblio: Marie-Karelle Riviere, Ying Yuan, Jacques-Henri Jourdan, Frédéric Dubois, Sarah Zohar. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research, 2016, ⟨10.1177/0962280216631763⟩. ⟨hal-01298681⟩
Accès au texte intégral et bibtex

ref_biblio: Caroline Petit, Vincent Jullien, Adeline Samson, Jérémie Guedj, Jean-René Kiechel, et al.. Designing a paediatric study for an antimalarial drug including prior information from adults. Antimicrobial Agents and Chemotherapy, 2016, 60 (3), pp.1481-1491. ⟨10.1128/AAC.01125-15⟩. ⟨hal-01255863⟩
Accès au texte intégral et bibtex

ref_biblio: Steffen Unkel, Christian Röver, Nigel Stallard, Norbert Benda, Martin Posch, et al.. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases, 2016, 11, pp.16. ⟨10.1186/s13023-016-0402-6⟩. ⟨hal-01286678⟩
Accès au texte intégral et bibtex

ref_biblio: Marie-Karelle Riviere, Sarah Zohar. Comments on ‘A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies’. Statistics in Medicine, 2016, 35 (3), pp.475-478. ⟨10.1002/sim.6630⟩. ⟨inserm-02456674⟩
Accès au bibtex

ref_biblio: Marie-Karelle Riviere, Jacques-Henri Jourdan, Sarah Zohar. dfcomb: An R-package for phase I/II trials of drug combinations. Computer Methods and Programs in Biomedicine, 2016, 125, pp.117-133. ⟨10.1016/j.cmpb.2015.10.018⟩. ⟨hal-01297367⟩
Accès au texte intégral et bibtex

2015

Journal articles

ref_biblio: Caroline Petit, Adeline Samson, Jérémie Guedj, Jean-René Kiechel, Emmanuelle Comets, et al.. Bumetanide for neonatal seizures—back from the cotside. Nature Reviews Neurology, 2015, 11 (12), pp.724-724. ⟨10.1038/nrneurol.2015.116⟩. ⟨inserm-02456688⟩
Accès au bibtex

ref_biblio: Satoshi Teramukai, Takashi Daimon, Sarah Zohar. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. Statistics in Medicine, 2015, 34 (22), pp.3029-3039. ⟨10.1002/sim.6550⟩. ⟨inserm-02456694⟩
Accès au bibtex

ref_biblio: Ronit Pressler, Geraldine Boylan, Neil Marlow, Mats Blennow, Catherine Chiron, et al.. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. The Lancet Neurology, 2015, 14 (5), pp.469-477. ⟨10.1016/S1474-4422(14)70303-5⟩. ⟨inserm-02456704⟩
Accès au bibtex

ref_biblio: M.-K. Riviere, Y. Yuan, F. Dubois, Sarah Zohar. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. Journal of the Statistical Society of London, 2015, 64 (1), pp.215-229. ⟨10.1111/rssc.12072⟩. ⟨hal-01298649⟩
Accès au texte intégral et bibtex

ref_biblio: Marie-Karelle Riviere, Frédéric Dubois, Sarah Zohar. Response to comments on ‘Competing designs for drug combination in phase I dose-finding clinical trials’ by G. Yin, R. Lin and N. Wages. Statistics in Medicine, 2015, 34 (1), pp.23-26. ⟨10.1002/sim.6332⟩. ⟨hal-01298661⟩
Accès au texte intégral et bibtex

ref_biblio: Marie-Karelle Riviere, C. Le Tourneau, X. Paoletti, F. Dubois, Sarah Zohar. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Annals of Oncology, 2015, 26 (4), pp.669-674. ⟨10.1093/annonc/mdu516⟩. ⟨hal-01298650⟩
Accès au texte intégral et bibtex

2014

Journal articles

ref_biblio: Marie-Karelle Riviere, Ying Yuan, Frédéric Dubois, Sarah Zohar. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics, 2014, 13 (4), pp.247-257. ⟨10.1002/pst.1621⟩. ⟨hal-01298657⟩
Accès au texte intégral et bibtex

2013

Journal articles

ref_biblio: Monia Ezzalfani, Sarah Zohar, Rui Qin, Sumithra Mandrekar, Marie-Cécile Le Deley. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Statistics in Medicine, 2013, 32 (16), pp.2728-2746. ⟨10.1002/sim.5737⟩. ⟨inserm-02456722⟩
Accès au bibtex

ref_biblio: Sarah Zohar. Modeling of experts’ divergent prior beliefs for a sequential phase III clinical trial. Clinical Trials, 2013, 10 (4), pp.505-514. ⟨10.1177/1740774513493528⟩. ⟨hal-04126310⟩
Accès au bibtex

ref_biblio: C. Le Tourneau, X. Paoletti, Marie-Karelle Riviere, Ying Yuan, Frédéric Dubois, et al.. Modeling of experts’ divergent prior beliefs for a sequential phase III clinical trial. Clinical Trials, 2013, 10 (4), pp.505-514. ⟨10.1177/1740774513493528⟩. ⟨inserm-02456716⟩
Accès au bibtex

ref_biblio: Takashi Daimon, Sarah Zohar. An adaptive model switching approach for phase I dose-finding trials. Pharmaceutical Statistics, 2013, 12 (4), pp.225-232. ⟨10.1002/pst.1578⟩. ⟨inserm-02456731⟩
Accès au bibtex

ref_biblio: Sarah Zohar, Matthieu Resche-Rigon, Sylvie Chevret. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clinical Trials, 2013, 10 (3), pp.414-421. ⟨10.1177/1740774511411593⟩. ⟨inserm-02456741⟩
Accès au bibtex

ref_biblio: Abhinav Kant, Pawan Kumar Gupta, Sarah Zohar, Sylvie Chevret, Philip Hopkins. Application of the Continual Reassessment Method to Dose-finding Studies in Regional Anesthesia. Anesthesiology, 2013, 119 (1), pp.29-35. ⟨10.1097/ALN.0b013e31829764cf⟩. ⟨inserm-02456728⟩
Accès au bibtex

2012

Journal articles

ref_biblio: Satoshi Teramukai, Takashi Daimon, Sarah Zohar. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. Statistics in Medicine, 2012, 31 (30), pp.4243-4254. ⟨10.1002/sim.5505⟩. ⟨inserm-02456748⟩
Accès au bibtex

ref_biblio: Mircea Chirica, Matthieu Resche-Rigon, Nicolas Munoz Bongrand, Sarah Zohar, Bruno Halimi, et al.. Surgery for Caustic Injuries of the Upper Gastrointestinal Tract. Annals of Surgery, 2012, 256 (6), pp.994-1001. ⟨10.1097/SLA.0b013e3182583fb2⟩. ⟨inserm-02456754⟩
Accès au bibtex

2011

Journal articles

ref_biblio: Sarah Zohar, Sandrine Katsahian, John O’Quigley. An approach to meta-analysis of dose-finding studies. Statistics in Medicine, 2011, 30 (17), pp.2109-2116. ⟨10.1002/sim.4121⟩. ⟨inserm-02456762⟩
Accès au bibtex

ref_biblio: Alexia Iasonos, Sarah Zohar, John O’Quigley. Incorporating lower grade toxicity information into dose finding designs. Clinical Trials, 2011, 8 (4), pp.370-379. ⟨10.1177/1740774511410732⟩. ⟨inserm-02456758⟩
Accès au bibtex

ref_biblio: Sarah Zohar, Ileana Baldi, Guido Forni, Franco Merletti, Giuseppe Masucci, et al.. Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas. Pharmaceutical Statistics, 2011, 10 (3), pp.218-226. ⟨10.1002/pst.450⟩. ⟨inserm-02456773⟩
Accès au bibtex

2010

Journal articles

ref_biblio: John O’Quigley, Sarah Zohar. Retrospective Robustness of the Continual Reassessment Method. Journal of Biopharmaceutical Statistics, 2010, 20 (5), pp.1013-1025. ⟨10.1080/10543400903315732⟩. ⟨inserm-02456779⟩
Accès au bibtex

2009

Journal articles

ref_biblio: Emmanuelle Comets, Sarah Zohar. A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology.: Reporting PK in phase I clinical trials. Clinical Pharmacokinetics, 2009, 48 (6), pp.387-395. ⟨10.2165/00003088-200948060-00004⟩. ⟨inserm-00409057⟩
Accès au texte intégral et bibtex

ref_biblio: Etienne Merlin, Sarah Zohar, C. Jérôme, Richard Veyrat-Masson, Geoffroy Marceau, et al.. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?. Bone Marrow Transplantation, 2009, 43 (12), pp.919-25. ⟨10.1038/bmt.2008.412⟩. ⟨inserm-00435572⟩
Accès au bibtex

ref_biblio: Sarah Zohar, Jacques Medioni, Celeste Lebbe, Marie-Françoise Avril, Delphine Kérob, et al.. Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. Melanoma Research, 2009, 19 (6), pp.379-384. ⟨10.1097/CMR.0b013e3283281042⟩. ⟨inserm-02456782⟩
Accès au bibtex

2008

Journal articles

ref_biblio: Sarah Zohar, Satoshi Teramukai, Yinghui Zhou. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial. Contemporary Clinical Trials Communications, 2008, 29 (4), pp.608-616. ⟨10.1016/j.cct.2007.11.005⟩. ⟨inserm-02456790⟩
Accès au texte intégral et bibtex